

Table I. *Patient characteristics.*

Patient	Age, years	Diagnosis	Histology	Stage (FIGO)	Recommended	Chemotherapy	EBRT dose, Gy/fractions	Reason ineligible for BT	SBRT boost dose, Gy/fractions
1	79	Cervix	SCC	IIIC	CHT + EBRT+ BT	None	61.6/28	Patient refusal	20/4
2	50	Cervix	SCC	IIB	CHT + EBRT+ BT	Cisplatin	61.6/28	Patient refusal	21/3
3	67	Cervix	SCC	IIB	CHT + EBRT+ BT	Cisplatin	60/30	Cervical stenosis	18/3
4	75	Cervix	SCC	IIA	CHT + EBRT+ BT	Cisplatin	61.6/28	Cervical stenosis	21/3
5	38	Cervix	SCC	IIA	CHT + EBRT+ BT	Cisplatin	61.6/28	Glanzmann's thrombasthenia	15/3
6	57	Cervix	SCC	IVA	CHT + EBRT+ BT	Cisplatin	61.6/28	Cervical stenosis	15/3
7	50	Cervix	SCC	IVA	CHT + EBRT+ BT	Carboplatin	61.6/28	Thrombocytopenia	15/3
8	58	Cervix	SCC	IIIB	CHT + EBRT+ BT	Cisplatin	61.6/28	Cervical stenosis	18/3
9	46	Cervix	ADC	IIA	TAH-BSO + EBRT + BT	Cisplatin	50.4/28	Cervical stenosis	25/5

ADC: Adenocarcinoma; BT: brachytherapy; EBRT: external beam radiation therapy; SCC: squamous cell carcinoma; TAH-BSO: total abdominal hysterectomy and bilateral salpingo-oophorectomy.